New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
September 20, 2019 - The FDA announced the approval of Novo Nordisk’s Rybelsus (semaglutide), as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Download PDF
Return to publications
